Featured Article

Call to Action Issued to Address Ongoing Osteoporosis Treatment Crisis

Call to Action Issued to Address Ongoing Osteoporosis Treatment Crisis

Kenneth Saag, MD, president of the National Osteoporosis Foundation (NOF), co-chair of the National Bone Health Alliance, and Rheumatology Advisor advisory board member, reports on the recent changes that have led to the current state of osteoporosis treatment in the US.

Latest News

Serotonin Levels Predict Increased Risk for Hip Fracture, Nonvertebral Osteoporotic Fracture

Serotonin Levels Predict Increased Risk for Hip Fracture, Nonvertebral Osteoporotic Fracture

High levels of serotonin are predictive of an increased risk for hip fracture, nonvertebral osteoporotic fracture, and incident fractures in older men.

Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women

Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women

Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.

Higher Groin C Avidum Colonization in Obese Patients After Hip Arthroplasty

Higher Groin C Avidum Colonization in Obese Patients After Hip Arthroplasty

Researchers assessed the incidence of Cutibacterium avidum infection in patients following primary hip arthroplasty.

Examining Bone Microarchitecture, Strength in Older Men With Accelerated Bone Loss

Examining Bone Microarchitecture, Strength in Older Men With Accelerated Bone Loss

Men with accelerated bone loss have lower estimated bone strength, poorer trabecular microarchitecture, and thinner cortices compared with men without accelerated bone loss.

Associations Between Site-Specific BMD, Anthropometric, Glucose Homeostasis Traits

Associations Between Site-Specific BMD, Anthropometric, Glucose Homeostasis Traits

Negative effects of 2-hour glucose was pronounced at the cortical-bone-dominant sites in women.

Prolia Approved for Glucocorticoid-Induced Osteoporosis

Prolia Approved for Glucocorticoid-Induced Osteoporosis

The FDA has approved use of Prolia for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture.

Effects of the 2 Types of Anorexia Nervosa on Bone Metabolism

Effects of the 2 Types of Anorexia Nervosa on Bone Metabolism

Investigators sought to determine whether both restrictive and purging types of anorexia nervosa effect bone metabolism.

Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss

Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss

An osteoporosis treatment may have a positive effect on human hair follicles from those undergoing hair transplantation surgery.

Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up

Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up

The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).

Subclinical Thyroid Dysfunction Not Associated With Hip Fracture Risk in Older Men

Subclinical Thyroid Dysfunction Not Associated With Hip Fracture Risk in Older Men

Findings do not support a role for subclinical thyroid dysfunction as a biomarker for bone-related outcomes in older men.

Sign Up for Free e-newsletters